TORASEMIDE FOR THE TREATMENT OF HEART FAILURE

Abstract

Diuretics play a major role in the rst line treatment for the Congestive Heart Failure (CHF). These diuretics are currently and majorly used for symptomatic relief. Torasemide, a loop diuretic, is a newly developed loop diuretic, which has a longer half-life, longer duration for action, and higher bioavailability as compared to the other loop diuretics like furosemide. Torasemide, also works more effectively for the anti-aldosterone effect and vasorelaxation effect. Several studies have also suggested that torasemide has superior pharmacokinetics and pharmacological activities than that of furosemide. Results of several studies state that torasemide helps in improving the left ventricular function, reduces the mortality, as well as the frequency and duration of heart failure. Torasemide also improves the quality of life, tolerance and NYHA functional class in patients suffering from CHF. Based on these results, torasemide appears to be a promising loop diuretic for the rst line treatment and for better management of the patients with CHF. In this review, we provide a panorama of existing knowledge on the properties of torasemide, aimed at using it as a rst line of treatment for the patients in Congestive Heart Failure (CHF).